CECILIA WANG: Open Payments
NPI 1083780753 · WAYNE, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,265 in 83 payments from 13 companies in 2025. Trend: 2023 $859 · 2024 $1,067 · 2025 $1,265
Food & beverage: $1,155Education: $109
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 18 | $257 |
| Teva Pharmaceuticals USA, Inc. | 11 | $232 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $179 |
| ABBVIE INC. | 16 | $176 |
| E.R. Squibb & Sons, L.L.C. | 5 | $81 |
| Vanda Pharmaceuticals Inc. | 5 | $79 |
| Alkermes, Inc. | 4 | $72 |
| Validus Pharmaceuticals LLC | 3 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Neos Therapeutics, LP | 2 | $39 |
Products named: REXULTI, CAPLYTA, VRAYLAR, AUSTEDO XR, COBENFY, ARISTADA, HETLIOZ, TRINTELLIX.
Industry payments across NJ — which companies pay providers there.
